Eagle Pharmaceuticals (EGRX) Stock Overview
A pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
EGRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Eagle Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.36 |
| 52 Week High | US$3.87 |
| 52 Week Low | US$0.0011 |
| Beta | 0 |
| 1 Month Change | 4.29% |
| 3 Month Change | 46.00% |
| 1 Year Change | -81.19% |
| 3 Year Change | -98.26% |
| 5 Year Change | -99.10% |
| Change since IPO | -97.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| EGRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.7% | -4.9% | -1.0% |
| 1Y | -81.2% | 28.1% | 23.3% |
Return vs Industry: EGRX underperformed the US Biotechs industry which returned 30% over the past year.
Return vs Market: EGRX underperformed the US Market which returned 24.4% over the past year.
Price Volatility
| EGRX volatility | |
|---|---|
| EGRX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: EGRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine EGRX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Mike Graves | www.eagleus.com |
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company’s product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults.
Eagle Pharmaceuticals, Inc. Fundamentals Summary
| EGRX fundamental statistics | |
|---|---|
| Market cap | US$4.89m |
| Earnings (TTM) | US$11.95m |
| Revenue (TTM) | US$257.55m |
Is EGRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EGRX income statement (TTM) | |
|---|---|
| Revenue | US$257.55m |
| Cost of Revenue | US$77.68m |
| Gross Profit | US$179.88m |
| Other Expenses | US$167.93m |
| Earnings | US$11.95m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did EGRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/19 15:17 |
| End of Day Share Price | 2026/05/19 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eagle Pharmaceuticals, Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| Irina Rivkind Koffler | Mizuho Securities USA LLC |
| David Amsellem | Piper Sandler Companies |